Synergy Empire LTD

Synergy Empire Limited has finalized its acquisition of Meluha Therapeutics Berhad, issuing 10 million shares of Series A preferred stock.

Synergy Empire Limited has engaged J&S Associate PLT as its new independent registered public accounting firm, effective immediately as of April 23, 2025.

Synergy Empire Limited reports the resignation of JP Centurion & Partners PLT as their independent registered public accounting firm, effective immediately as of January 20, 2025, and the appointment of a new firm is not mentioned.

Synergy Empire Limited has completed the acquisition of Meluha Therapeutics Berhad, marking a strategic shift from the food and beverage industry to healthcare and pharmaceuticals.

Synergy Empire Limited has acquired Meluha Therapeutics Berhad by issuing 10 million shares of Series A Preferred Stock in exchange for all outstanding ordinary shares of Meluha, resulting in a significant change in Synergy Empire's voting power.

Synergy Empire Limited has amended its articles of incorporation to increase the number of authorized common and preferred shares and has created a new Series A Preferred Stock.

Synergy Empire Limited reports Q3 2025 results, detailing a strategic pivot to biopharmaceutical contract manufacturing following the acquisition of Meluha Therapeutics Berhad.

Synergy Empire Limited reports Q2 2025 results, detailing a strategic pivot to biopharmaceutical contract manufacturing following a reverse takeover.

Synergy Empire Limited reports Q1 2025 revenue of $12,500, a significant increase from zero in the prior year, driven by its new consultancy services business.

Synergy Empire Limited's Q3 2024 results show a significant revenue decrease due to the termination of tenancy agreements, offset by new lease revenue.

Synergy Empire Limited reports a significant decrease in revenue and a shift in business strategy towards consultancy services for the fiscal year ended March 31, 2024.